Results 11 to 20 of about 26,337 (144)

Language Fluency Deficits in Post-treatment Lyme Disease Syndrome. [PDF]

Arch Clin Neuropsychol, 2023
Abstract Objective Recent neurocognitive studies of patients with post-treatment Lyme disease syndrome (PTLDS) find consistent deficits in memory and processing speed. Language fluency deficits are observed as well but may be secondary to poor memory and slowing rather than an independent deficit.
Gorlyn M, Keilp JG, Fallon BA.
europepmc   +3 more sources

Reassessing Chronic Lyme Disease and Post-Treatment Lyme Disease Syndrome as Focal Infections. [PDF]

Cureus
The complete clinical spectrum of Lyme borreliosis has been recognized for nearly 50 years, yet its diagnosis remains challenging due to the heterogeneity of symptoms. While many symptoms are likely nonspecific, a recurring cluster, including severe fatigue, brain fog, cognitive decline, memory impairment, joint and muscle pain, limb numbness ...
Lakos A, Nagy G, Varga Z, Rásonyi-Kovács P, Hornok S.   +4 more
europepmc   +3 more sources

Cost of illness in patients with post-treatment Lyme disease syndrome in Belgium. [PDF]

Eur J Public Health, 2023
Abstract Background A proportion of patients with Lyme borreliosis (LB) report long-term persisting signs and symptoms, even after recommended antibiotic treatment, which is termed post-treatment Lyme disease syndrome (PTLDS).
Willems R, Verhaeghe N, Perronne C, Borgermans L, Annemans L.   +4 more
europepmc   +5 more sources

Post-Treatment Lyme Disease Syndrome: Need for Diagnosis and Treatment. [PDF]

Cureus, 2021
With the continued surge in Lyme disease cases, post-treatment Lyme disease syndrome (PTLDS) is becoming a more pressing health concern. The aim of this review is to identify comprehensive treatment strategies for PTLDS patients. Unfortunately, universal guidelines for diagnosing and treating PTLDS do not currently exist.
Maksimyan S, Syed MS, Soti V.
europepmc   +4 more sources

Seroprevalence of Antibodies against Tick-Borne Pathogens in Czech Patients with Suspected Post-Treatment Lyme Disease Syndrome. [PDF]

Microorganisms, 2021
Sloupenska K, Dolezilkova J, Koubkova B, Hutyrova B, Racansky M, Horak P, Golovchenko M, Raska M, Rudenko N, Krupka M.   +9 more
europepmc   +2 more sources

Invalidation by medical professionals in post-treatment Lyme disease. [PDF]

Sci Rep
Patients with post-treatment Lyme disease (PTLD) report negative perceptions of care and significant invalidation from medical professionals. However, the relationship of invalidation to illness severity has not been examined, nor have risk factors for invalidation been identified.
Rebman AW, Yang T, Aucott JN.
europepmc   +4 more sources

Annexin A2 antibodies in post-treatment Lyme disease. [PDF]

Ther Adv Infect Dis
Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD). Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.
Miller JB, Rebman AW, de Flores MDV, Wang H, Darrah E, Aucott JN.   +5 more
europepmc   +4 more sources

Kundalini Yoga for Post-Treatment Lyme Disease: A Preliminary Randomized Study. [PDF]

Healthcare (Basel), 2022
This study examined the adherence to and the potential benefit of Kundalini yoga (KY) for post-treatment Lyme disease syndrome (PTLDS). Participants were randomly assigned to 8 weeks of a KY small-group intervention or a waitlist control (WLC). Adherence was measured as attendance at KY group sessions. Primary outcomes assessed pain, pain interference,
Murray L, Alexander C, Bennett C, Kuvaldina M, Khalsa G, Fallon B.   +5 more
europepmc   +3 more sources

Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome. [PDF]

Clin Infect Dis, 2021
Abstract Background Post-treatment Lyme disease symptoms/syndrome (PTLDS) occurs in approximately 10% of patients with Lyme disease following antibiotic treatment. Biomarkers or specific clinical symptoms to identify patients with PTLDS do not currently exist and the PTLDS classification is based on ...
Fitzgerald BL, Graham B, Delorey MJ, Pegalajar-Jurado A, Islam MN, Wormser GP, Aucott JN, Rebman AW, Soloski MJ, Belisle JT, Molins CR.   +10 more
europepmc   +4 more sources

Pilot study of psilocybin in patients with post-treatment lyme disease. [PDF]

Sci Rep
Abstract Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a ...
Garcia-Romeu A, Naudé GP, Rebman AW, So S, Yaffe A, Geithner I, Kozero EA, Yang T, Soloski MJ, Aucott JN.   +9 more
europepmc   +2 more sources